medigraphic.com

2018, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2018; 56 (3)

Obesity and adipocytokines in breast cancer and benign breast disease

Quiroga-Morales LA, Sat-Muñoz D, Martínez-Herrera BE, Alcántara-Cadillo RR, Macías-López GG, García-Cobián TA, Bañuelos-Rizo M, Balderas-Peña LMA

Language: Spanish
References: 33
Page: 246-254
PDF size: 902.54 Kb.


ABSTRACT

Background: There is a relationship between obesity and the development of breast cancer; adipocytokines are among the mechanisms related.
Objective: To describe the impact of obesity in leptin, adiponectin, resistin and tumor necrosis factor-alpha (TNF-alpha) serum levels in women with breast cancer (BC) and benign breast disease (BBD).
Methods:A cross-sectional study was carried out with a sample of 54 individuals divided into two groups: BC (n = 27) and BBD (n = 27). Serum levels of leptin, adiponectin, resistin and TNF-alpha were determined. Body mass index (BMI) was calculated. Statistical analysis included mean, standard deviation, median and interquartile range; the differences between groups were determined by Student´s t test, Mann-Whitney U and Kruskall Wallis test to identify differences between the groups.
Results: We didn’t find any significant differences related to anthropometric characteristics between BC and BBD groups, or to leptin, adiponectin, resistin and TNF-alpha serum levels (p = NS). We found higher leptin serum levels in obese women with BBD compared with non-obese women with BC (med 22.26 versus 4.34 ng/mL; p = 0.028). Adiponectin serum levels in nonobese women from the BC group were higher than serum levels found in non-obese women with BBD (med 7.10 versus 2.22 ng/mL; p = 0.038)
Conclusion: We found higher leptin serum levels and lower adiponectin serum levels in BBD women than BC women in this population with high frequency of obesity.


REFERENCES

  1. Szabová M, Jahnová E, Horváthová M, Ilavská S, Pružincová V, Nemessányi T, et al. Changes in immunologic parameters of humoral immunity and adipocytokines in obese persons are gender dependent. Hum Immunol. 2012 May;73(5):486-92. doi: 10.1016/j.humimm.2012.02.006.

  2. World Cancer Research Fund/American Institute for Cancer Research (AICR). Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR; 2007.

  3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X.

  4. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003 Aug;4(3):157-73.

  5. Porter GA, Inglis KM, Wood LA, Veugelers PJ. Effect of obesity on presentation of breast cancer. Ann Surg Oncol. 2006 Mar;13(3):327-32.

  6. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol. 1997 Jun;26(3):484- 90.

  7. Assiri AM, Kamel HF, Hassanien MF. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015;2015:253519. doi: 10.1155/2015/253519.

  8. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134.

  9. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014 Aug 30;384(9945):755-65. doi: 10.1016/S0140-6736(14)60892-8. 2

  10. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1686-91.

  11. Vainio H, Bianchini F, editores. Weight Control and Physical Activity, Vol. 6. IARC Handbook of Cancer Prevention. Lyon, France: IARC Press; 2002. pp. 1-315.

  12. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. 2004 Feb;150(2):161-71

  13. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007 Sep;8(5):395-408.

  14. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007 Jun;14(2):189- 206.

  15. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors. 2014 Jan- Feb;40(1):1-12. doi: 10.1002/biof.1109.

  16. Simone V, D'Avenia M, Argentiero A, Felici C, Rizzo FM, De Pergola G, et al. Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. Oncologist. 2016 Apr;21(4):404-17. doi: 10.1634/theoncologist.2015-0351.

  17. Ilavská S, Horváthová M, Szabová M, Nemessányi T, Jahnová E, Tulinská J, et al. Association between the human immune response and body mass index. Hum Immunol. 2012 May;73(5):480-5. doi: 10.1016/j.humimm.2012.02.023.

  18. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920.

  19. Montaruli, A, Patrini, P, Roveda, Caradente F. Physical activity and breast cancer. Sport Sci Health 2012;8:1-13. doi:10.1007/s11332-012-0125-6

  20. Huang NS, Quan CL, Mo M, Chen JJ, Yang BL, Huang XY, et al. A prospective study of breast anthropomorphic measurements, volume and ptosis in 605 Asian patients with breast cancer or benign breast disease. PLoS One. 2017;12(2):e0172122. doi: 10.1371/journal.pone.0172122. eCollection 2017.

  21. Visscher DW, Frank RD, Carter JM, Vierkant RA, Winham SJ, Heinzen EP, et al. Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx035.

  22. Schnitt SJ, Morrow M, Tung NM. Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx036.

  23. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. Obes Rev. 2015 Jun;16(6):473-87. doi: 10.1111/obr.12281.

  24. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006 Oct;6(10):772-83.

  25. Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, et al. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2. pii: 16032. doi: 10.1038/npjbcancer.2016.32.

  26. Vierkant RA, Degnim AC, Radisky DC, Visscher DW, Heinzen EP, Frank RD, et al. Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer. 2017;17(1):84. doi: 10.1186/s12885-017-3082-2.

  27. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga- Koda L, Golaszewska J, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006 Mar 1;12(5):1447-53.

  28. Santillán-Benítez JG, Mendieta-Zerón H, Gómez-Oliván LM, Torres-Juárez JJ, González-Bañales JM, Hernández- Peña LV, et al. The tetrad BMI, leptin, leptin/adiponectin 4 (L/A) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013;27(1):12-20. doi: 10.1002/jcla.21555.

  29. Guitérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales [Internet]. Cuernavaca, México: Instituto Nacional de Salud Pública (MX); 2012. Disponible en http://ensanut.insp.mx/informes/ENSANUT2012Resultados Nacionales.pdf [Consultado el 11 de julio de 2016].

  30. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat. 2012 Jul;134(2):769-81. doi: 10.1007/s10549-012- 2073-x.

  31. Chajès V, Romieu I. Nutrition and breast cancer. Maturitas, 2014; 77(1): 7-1. DOI: http://dx.doi.org/10.1016/j.maturitas.2013.10.004

  32. Endogenous Hormones and Breast Cancer Collaborative Group. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids. 2015 Jul;99(Pt A):49-55. doi: 10.1016/j.steroids.2014.09.001.

  33. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26.




2020     |     www.medigraphic.com